

CURRICULUM VITAE

Dai Maruyama, M.D., Ph.D.

Office Address

Department of Hematology Oncology,
Cancer Institute Hospital, Japanese Foundation for Cancer Research
3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan
TEL: +81-3-3520-0111
E-mail: dai.maruyama@jfcrr.or.jp

Education and Qualifications

1993-1999	M.D., Jikei University School of Medicine
1999-2001	Resident of Internal Medicine, Jikei University Hospital
2001-2002	Fellow of Hematology and Oncology Division, Jikei University Hospital
2002-2003	Medical staff of Internal Medicine, Omori Red Cross Hospital
2003-2004	Clinical Associate of Hematology and Oncology Division, Jikei University Hospital
2004-2006.3	Fellow (chief-resident) of Hematology and Hematopoietic Cell Transplantation Division, National Cancer Center Hospital
2006.4-2006.9	Clinical Associate of Hematology and Oncology Division, Jikei University Hospital
2006.10-2008.12	Staff physician, Hematology Division, National Cancer Center Hospital, and Officer of cancer training, National Cancer Center, Center for Cancer Control and Information Services
2008	Degree of Ph.D. from Jikei University School of Medicine
2009-2013	Staff physician, Hematology Division, National Cancer Center Hospital
2013-2020.12	Head of medical staff, Department of Hematology, National Cancer Center Hospital
2021.01-present	Director, Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research

2022.11-2023.09	Director, Center for Development of Advanced Cancer Therapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research
2023.06-present	Junior Hospital Director, Cancer Institute Hospital, Japanese Foundation for Cancer Research

Research interests

Malignant Lymphoma, Multiple Myeloma, Clinical Trial, Chemotherapy, Antibody Therapy, Molecular-Targeting Therapy, Immunotherapy

Award

2012	Japan Clinical Oncology Group (JCOG) Most Active Physician Award
2020	Japan Clinical Oncology Group (JCOG) Best Study Coordinator Award

Medical Societies

- Japanese Society of Internal Medicine
- Japanese Society of Hematology
- Japanese Society of Lymphoreticular Tissue Research
- Japan Society for Hematopoietic Cell Transplantation
- Japanese Society of Medical Oncology
- Japanese Cancer Association
- Japanese Society of Myeloma
- American Society of Hematology
- American Society of Clinical Oncology
- European Hematology Association

Research Grants (PI only)

- Principal investigator: Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control)
[2015-2016] [2017-2019] [2021-2023] [2024-]

Research Activities (Clinical Trials)

- Core member of Protocol Review Committee of JCOG Lymphoma Study Group (JCOG-LSG)
- Coordinating Office of JCOG1105 trial (focusing on transplant-ineligible myeloma)
- Coordinating Office of JCOG1411 (focusing on low tumor burden follicular lymphoma)
- Principal investigator of JCOG1911 (focusing on transplant-ineligible myeloma)
- Secretariat of JCOG-LSG (2012-2023)
- Member, Japanese Society of Hematology, Practical Guidelines for Hematological Malignancies: Burkitt lymphoma and Peripheral T-cell lymphoma/Extranodal NK/T-cell lymphoma
- Member, Japan Society of Clinical Oncology, Clinical Practice Guidelines for the Use of G-CSF
- Member, Japanese Society of Medical Oncology, Onco-Cardiology Guidelines
- WHO classification, Haematolymphoid Tumours, 5th edition. Co-author of Lymphoplasmacytic lymphoma and Plasma cell myeloma/multiple myeloma
- Coordinating Office of Nation-wide survey of HBs-antigen-positive DLBCL in Japan
- Journal of Clinical and Experimental Hematopathology, Editorial Board (-2017)
- Japanese Journal of Clinical Oncology, Associated Editor (2017-)
- 17-International Conference on Malignant Lymphoma Closed Workshop member (2023)